Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 23;138(25):2696–2701. doi: 10.1182/blood.2021012732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Novel NPM1 gene mutations involving exon 5. (A) IHC staining of BM trephine from PG patients 1, 2, and 3 showing diffuse infiltration by leukemic blasts (hematoxylin and eosin [HE], upper) with aberrant cytoplasmic positivity for NPM1 (NPM1, lower). Besides cytoplamic staining, nucleoli staining is shown in the inset (white arrows) for PG patients 1 and 3. NPM1 staining: mouse monoclonal clone 376 anti-NPM1 N-terminus by antialkaline phosphatase technique with hematoxylin counterstaining. Images were collected using an Olympus B61 microscope with a UPlanApo 40×/0.85 U (40× magnification) and UPlan FI 100×/1.3 NA oil (×100 original magnification) objective for the inset, Camedia 4040 (Dp_soft version 3.2), and Adobe Photoshop CC 2019. (B) WB analysis of total protein extracts from PG patient 1 showing the reactivity pattern with the different anti-NPM1 antibodies (supplemental Figure 1). Specifically, although the anti-NPM1 mutant did not show positivity (left), the anti-NPM WT recognized, besides the known WT NPM1 protein at 37 kDa, a band at a slightly higher molecular weight (middle; asterisk). This was also recognized by clone 376, indicating it was NPM1 (pan-NPM1; right; asterisk). (C) Graphical representation and predicted protein sequence of the new NPM1 exon 5 mutants. Nucleotides insertion points are indicated for each mutation (a,b,c,d) according to the NPM1 complementary DNA transcript ENST00000296930. The newly acquired amino acids (aa) are highlighted in red, and the predicted NES motif is underlined. Mutants from PG patient 1, PG patient 3, and MLL patient 4 retain the C-terminus of the WT NPM1 (nucleolar localization signal [NoLS]; yellow). Representative image of NIH-3T3 overexpressing the new GFP-NPM1 exon 5 fusion protein from MLL patient 4 showing the aberrant localization in the cytoplasm and, concomitantly, in the nucleoli (right; white arrow). Images were acquired using a Zeiss LSM 800 confocal microscope (Carl Zeiss) with a 488-nm (for eGFP) laser line for excitation and 63×/1.4 oil Plan-Apochromat objective (×63 original magnification). (D) Table illustrating the most relevant characteristics of patients with AML carrying NPM1 exon 5 mutations. BMT, BM allogeneic transplantation; CR, complete remission; Hb, hemoglobin; IC, standard intensive chemotherapy; MK, megakaryocytes; MLD, multilineage dysplasia; NA, not available; PLT, platelets; pt., patient; VAF, variant allele frequency; WBC, white blood cells.